Abstract 5753: RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth

@inproceedings{Hatzivassiliou2010Abstract5R,
  title={Abstract 5753: RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth},
  author={Georgia Hatzivassiliou and Kyung Song and Ivana Yen and Barbara J. Brandhuber and Daniel J Anderson and Ryan Alvarado and Mary J. C. Ludlam and David Stokoe and Susan L. Gloor and Guy P. A. Vigers and Tony H Morales and Ignacio Aliagas and Bonnie Rui Liu and Steve Sideris and Klaus P. Hoeflich and Bijay S. Jaiswal and Somasekar Seshagiri and Hartmut Koeppen and Marcia Belvin and Lori S. Friedman and Shiva Malek},
  year={2010}
}
  • Georgia Hatzivassiliou, Kyung Song, +18 authors Shiva Malek
  • Published 2010
  • Biology
  • Proceedings: AACR 101st Annual Meeting 2010‐‐ Apr 17‐21, 2010; Washington, DC Activating mutations in KRAS or B-RAF are found in over 30% of all human tumors and targeting this pathway could have broad therapeutic impact. Small molecule ATP-competitive RAF kinase inhibitors have potent anti-tumor effects on B-RAFV600E tumors but, in contrast to MEK inhibitors, are not potent against RAS mutant tumor models, despite RAF functioning as a key effector downstream of RAS and upstream of MEK. In… CONTINUE READING

    Create an AI-powered research feed to stay up to date with new papers like this posted to ArXiv

    Citations

    Publications citing this paper.
    SHOWING 1-4 OF 4 CITATIONS